HT
MRSN

HAP Trading’s Mersana Therapeutics MRSN Stock Holding History

HAP Trading’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,583
Closed -$524K – 1273
2023
Q1 		$368K Buy
+3,583
New +$503K 0.06% 226
2021
Q1 		– Sell
-452
Closed -$301K – 2192
2020
Q4 		$301K Buy
+452
New +$251K 0.01% 813

Other funds holding MRSN

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

HAP Trading's MRSN Position: Q2 2023 in Review

HAP Trading sold out of Mersana Therapeutics (MRSN) in Q2 2023, closing a stake of 3,583 shares — an estimated $524K sold.

HAP Trading first reported a position in MRSN in Q4 2020 and held it in 2 quarters. The position peaked at $368K in Q1 2023. 147 funds tracked by Wall St. Rank hold MRSN as of Q2 2023.

  • HAP Trading reported no remaining Mersana Therapeutics position as of Q2 2023 after selling out during the quarter.
  • HAP Trading sold 3,583 Mersana Therapeutics shares in Q2 2023, an estimated $524K.
  • HAP Trading first reported a position in Mersana Therapeutics in Q4 2020 and held it in 2 quarters.
  • HAP Trading's Mersana Therapeutics position peaked at $368K in Q1 2023.
  • 147 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2023.

Based on HAP Trading's 13F filing for Q2 2023, filed 11 Aug 2023.